Bass suffers another IPR setback
03-09-2015
Tupungato / Shutterstock.com (University of Pennsylvania campus, pictured)
Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review (IPR).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CFAD; Coalition for Affordable Drugs; Kyle Bass; University of Pennsylvania; PTAB; IPR; Juxtapid; anti-cholesterol; Celgene; USPTO
